T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.4% |
| 2 | Healthcare | 16.1% |
| 3 | Consumer Discretionary | 15.8% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1526
Ingredion
INGR
$6.63B
| $3.88M | ﹤0.01% |
40,130
-2,074
| -5% | -$200K |
|
1527
PubMatic
PUBM
$801M
| $3.88M | ﹤0.01% |
113,863
-63,792
| -36% | -$2.08M |
|
1528
Ovintiv
OVV
$17.4B
| $3.87M | ﹤0.01% |
114,796
-1,608
| -1% | -$57.4K |
|
1529
First Horizon
FHN
$12.4B
| $3.87M | ﹤0.01% |
236,702
-9,533
| -4% | -$159K |
|
1530
Vroom Inc
VRM
$56.8M
| $3.83M | ﹤0.01% |
4,441
+28
| +0.6% | +$37.7K |
|
1531
Omega Healthcare
OHI
$14.1B
| $3.82M | ﹤0.01% |
128,991
-6,422
| -5% | -$188K |
|
1532
Owens Corning
OC
$12.2B
| $3.81M | ﹤0.01% |
42,100
-561
| -1% | -$50.9K |
|
1533
Dolby
DLB
$5.84B
| $3.81M | ﹤0.01% |
39,965
-2,174
| -5% | -$195K |
|
1534
ManpowerGroup
MAN
$2.71B
| $3.8M | ﹤0.01% |
39,015
-1,303
| -3% | -$131K |
|
1535
Prelude Therapeutics
PRLD
$443M
| $3.79M | ﹤0.01% |
304,332
-90,944
| -23% | -$1.48M |
|
1536
iShares Russell 1000 ETF
IWB
$50.4B
| $3.74M | ﹤0.01% |
14,136
| – | – |
|
1537
Reinsurance Group of America
RGA
$16.3B
| $3.7M | ﹤0.01% |
33,753
-4,257
| -11% | -$473K |
|
1538
Atea Pharmaceuticals
AVIR
$410M
| $3.69M | ﹤0.01% |
412,915
-1,083,050
| -72% | -$16.9M |
|
1539
Macy's
M
$6.16B
| $3.67M | ﹤0.01% |
140,137
-19,126
| -12% | -$522K |
|
|
ATH
1540
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
| $3.66M | ﹤0.01% |
43,871
-1,940
| -4% | -$159K |
|
1541
First Solar
FSLR
$24.2B
| $3.65M | ﹤0.01% |
41,840
-1,669
| -4% | -$172K |
|
1542
MasTec
MTZ
$23.9B
| $3.62M | ﹤0.01% |
39,261
-932
| -2% | -$85.2K |
|
1543
Ares Management
ARES
$32.5B
| $3.61M | ﹤0.01% |
44,406
+4,940
| +13% | +$402K |
|
|
MGP
1544
DELISTED
MGM Growth Properties LLC Class A common shares representing limited liability company interests
MGP
| $3.6M | ﹤0.01% |
88,026
| – | – |
|
1545
Transmedics
TMDX
$3.07B
| $3.57M | ﹤0.01% |
+186,263
| New | +$4.67M |
|
1546
Jack in the Box
JACK
$325M
| $3.56M | ﹤0.01% |
40,753
+3,535
| +9% | +$328K |
|
1547
iShares Russell Mid-Cap Value ETF
IWS
$16.1B
| $3.56M | ﹤0.01% |
29,058
| – | – |
|
1548
Gentex
GNTX
$5.03B
| $3.54M | ﹤0.01% |
101,696
-26,644
| -21% | -$945K |
|
1549
Old Republic International
ORI
$10.3B
| $3.54M | ﹤0.01% |
143,814
-2,781
| -2% | -$69.1K |
|
1550
Prosperity Bancshares
PB
$9.02B
| $3.48M | ﹤0.01% |
48,126
-589,282
| -92% | -$43.6M |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.